The progestin megestrol acetate and the anti-estrogen tamoxifen are used as effective drugs in the treatment of metastatic breast cancer and have few side effects. The sequence and indications for use in practice still need to be defined. Of 219 postmenopausal patients with metastatic breast cancer and measurable lesions, 136 were treated with megestrol acetate (MA) per os (180 mg daily) and followed by tamoxifen (TAM) (40 mg daily) in cases with progression, and 83 patients were treated with the inverse drug regimen. In the first line treatment they showed similar effects: MA caused remission in 31/136 patients (23%) and TAM in 17/80 patients (22%) (mean duration 12 and 13 months respectively), while as a second treatment line MA caused remission in 14/83 patients (17%) and TAM in 12/132 patients (9%), which was not significant (P=0.10). Also with respect to survival there was no significant difference between the two treatment modalities.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mouridsen H, Palshof T: Tamoxifen in advanced breast cancer.Cancer Treatment Rev 5, 131 (1978).
Alexieva-Figusch J, Gilse H A van, Hop W C J, Phoa C H, Blonk-v.d.Wijst J, Treurniet R E: Progestin therapy in advanced breast cancer: megestrol acetate —an evaluation of 160 treated cases.Cancer 46, 2369 (1980).
Alexieva-Figusch J, Blankenstein M A, Hop W C J, Klijn J G M, Lamberts S W J, de Jong F H, Docter R, Adlercreutz H, van Gilse H A: Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.Eur J Cancer 20, 33 (1984).
Mattsson W, Von Heyben F, Hallsten L, Tennvall L: A phase III study of tamoxifen versus high dose medroxyprogesterone acetate (HD-MPA) in post-menopausal advanced breast cancer.Int Symp on MPA. Geneva, 24–25 February 1982.Excerpta Medica 276 (1982).
Beretta G. Tabiadon D, Luporini G: Clinical experience with medroxyprogesterone acetate in advanced breast cancer.Int Symp on MPA. Geneva, 24–25 February 1982.Excerpta Medica 285 (1982).
Camaggi C M: In F. Cavalliet al (eds): Round Table.Int Symp on MPA. Geneva, 24–26 February 1982.Excerpta Medica 185 (1982).
Hayward J L, Carbone P P, Heuson J C, Kumaoka S, Segaloff A, Rubens R D: Assessment of response to therapy in advanced breast cancer.Eur J Cancer 13, 89 (1977).
Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G: Design and analysis of randomised clinical trials requiring prolonged observation of each patient.Br J Urol 45, 586 (1977).
Fabian C, Sternson L A: Tamoxifen pharmacokinetics in patients with breast cancer: comparison of traditional and loading dose schedules.Reviews on Endocrine-Related Cancer, Suppl. 9, October, 155 (1981).
About this article
Cite this article
Alexieva-Figusch, J., van Putten, W.L.J., van Gilse, H.A. et al. Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study). Med. Oncol. & Tumor Pharmacother. 2, 69 (1985). https://doi.org/10.1007/BF02934851
- Breast cancer
- Megestrol acetate